mapping may be helpful but is not able to reliably differentiate between cardiac amyloidosis due to ATTR or to other types of amyloidosis. However, assessment of extracellular volume using quantitative T1 mapping (either native or before and after application of contrast agent) has been reported as a promising biomarker for moderate micro-morphological changes, which presumably are present in early stages of the disease [6] . Molecular imaging with PET and SPECT nowadays play a critical role in the diagnosis, identification and distinction between ATTR and AL type CA. Figure 1 shows the pathogenesis of amyloid deposition for the three major types, i.e. AL, ATTR and AA type in the heart. Increased thickness of the ventricular walls and strain differences (apical sparing) caused by extracellular deposition of amyloid can be detected by echocardiography. Delayed enhancement of gadolinium using MRI reflects an increased extravascular volume of the myocardial tissue. Serum amyloid P component (SAP) binds in a calcium-dependent way to all types of amyloid in many vital organs, but when labeled with 123 I, not to amyloid in the heart [7] . This may be caused by the lack of a fenestrated endothelium in the myocardium, hindering access of the large 125 kDa tracer to the extracellular space. Florbetapen is closely related to thioflavin T, a strong stain of amyloid that binds to repetitive motifs at the surface of the fibrils [8] . Bisphosphonates and pyrophosphate bind strongly to ATTR amyloid and weakly or not at all to AA and AL amyloid. Although there may be a relation with microcalcifications [9] , the bone tracer 18 F-NaF does not always show the same strong tracer retention in ATTR CA [10] . The specific binding is probably not only to calcium, but technetium can bind to some metals [11] and/or to sulfhydryl groups on ATTR amyloid [12, 13] . Aprotinin has been used in the past to detect CA [14] and it may bind to repetitive motifs and/or electrostatically [15] . MIBG normally accumulates in vesicles in sympathetic nerve endings close to myocardial cells and the reduced uptake and increased loss probably reflects myocardial cell damage caused by amyloid [16] . Tc-DPD bone scintigraphy [17] . Additionally, the use of 18 F-florbetaben-PET/ CT for quantification of amyloid burden, including myocardial tracer retention (MTR), and monitoring of treatment response was assessed. Myocardial 18 F-florbetaben retention was found consistent with CA in 14/22 patients. Suspicion of CA was subsequently dropped in all eight PET-negative patients. Amyloid subtypes showed characteristic retention patterns (AL > AA > ATTR; all p < 0.005). MTR correlated with morphologic and functional parameters, as measured by CMR and echo (all r > 0.47, all p < 0.05), but not with cardiac biomarkers. Changes in MTR from baseline to follow-up corresponded well to treatment response, as assessed by cardiac biomarkers and performance status.
The authors concluded that imaging of CA with 18 Fflorbetaben PET/CT is feasible and might be useful in differentiating CA subtypes. Although this study consisted of a small, heterogeneous patient cohort, including treatmentnaïve as well as pre-treated patients, it underlines the clinical value of applying new more specific PET imaging tracers in cardiac imaging. To demonstrate, however, the potential of amyloid-directed PET as a non-invasive instrument of (early) therapy monitoring, an understanding of the underlying biology is of utmost importance. Histological proof was lacking in the present study, including additional whole-body imaging to detect further sites of organ involvement in systemic amyloidosis, and this should be addressed in future studies.
More specific PET-imaging tracers in amyloidosis selectively bind to β-amyloid plaques and were originally designed as an aid to establish the clinical diagnosis of Alzheimer's disease. These specific radiopharmaceuticals are the benzothiazoles 11 C-Pittsburgh compound-B ( 11 C-PiB) and 18 F-florbetaben, while 18 F-florbetapir is a stilbene derivative with a very similar structure.
11
C-PiB as well as 18 F-florbetapir have been used as tracers for cardiac amyloid in patients with ATTR and AL cardiac amyloidosis [18, 19] . However, 11 C-PiB is only available in centers with an on-site cyclotron. Manwani et al. evaluated cardiac uptake with 18 F-florbetapir PET in patients with systemic AL amyloidosis and cardiac involvement before and after treatment, as well as its serial utility in monitoring in 15 patients [20] . There was a suggestion that treatment-naïve patients may have higher cardiac uptake. In addition, correlation of myocardial 18 F-florbetapir uptake with histological findings in 20 amyloidosis patients (10 AL and 10 ATTR) versus 10 control subjects revealed significantly lower specific 18 F-florbetapir binding in controls (p = 0.002) [21] . Specific 18 F-florbetapir binding in AL samples was significantly higher than in ATTR samples (p = 0.001). Furthermore, increase in 18 F-florbetapir binding on autoradiography correlated well with increasing echocardiography-derived LV wall mass, due to more advanced stages of the disease. More importantly, 18 F-florbetapir binding was already present in small amounts before LV wall thickness increased.
A recent systematic review of the application of PET imaging with 11 C-PiB, 18 F-florbetapir and 18 F-florbetaben in six studies (n = 98 subjects) demonstrated a sensitivity of 92% and a specificity of 83% for the detection of AL and ATTR CA [22] . Further, regular bone scintigraphy has emerged as a reliable, non-invasive tool to diagnose cardiac amyloidosis due to ATTR (either ATTRv or ATTRwt), with a sensitivity of 92.2% (95% CI 89-95%) and a specificity of 95.4% [23, 24] . The use of iodine-123 labelled metaiodobenzylguanidine ( 123 I-MIBG), a chemical modified analogue of norepinephrine, is well established in patients with heart failure and also plays an important role in the evaluation of sympathetic innervation in cardiac amyloidosis [25] .
Current treatments are targeted at reducing the production of or stabilisation of the precursor protein of amyloid deposits and thereby aim to stop or slow down further accumulation of amyloid. In AL amyloidosis, treatment is directed against light chain-producing plasma cells in order to normalize the light chain serum levels. Recently, genesilencing oligonucleotide drugs that inhibit hepatic synthesis of the precursor protein transthyretin proved to be Fig. 1 In the upper part the pathogenic pathways of AA, AL and ATTR, the major three types of amyloidosis, are shown vertically. In AA, chronic inflammation stimulates the liver to produce the acute phase protein SAA, that becomes cleaved and misfolded. In AL, clonal plasma cells in the bone marrow produce immunoglobulin light chains, of which the variable part becomes misfolded. In ATTR, the liver produces the tetrameric protein transthyretin, that dissociates into monomers that become misfolded. The misfolded precursor proteins aggregate, finally resulting in the formation of amyloid fibrils (AA shown in red, AL in blue, and ATTR in green). Without specific immunohistochemical staining, fibrils of different types are indistinguishable from each other under the microscope (shown in grey) The lower part of the figure is focused on imaging of amyloid deposition in the extracellular myocardial tissue. Echocardiography reveals increased wall thickness and stiffness, whereas late gadolinium enhancement in MRI reflects an increased volume of the extracellular myocardial tissue. Mechanisms used for molecular imaging of amyloid show specific binding of tracers to amyloid-specific elements of fibrils and related extracellular matrix in which the amyloid is anchored. Connected to amyloid in the extracellular matrix an increase of molecules such as serum amyloid P component (SAP), heparan sulphate (HS), apolipoprotein E (apoE), and laminin is found. Aprotinin and thioflavin-like agents (PiB, florbetapir and florbetapen) bind directly to repetitive motifs on the exterior surface of the fibrils. Technetium-labelled bone seeking agents (pyrophosphate and bisphosphonates) may bind to calcium, but also to metals (Zn, Fe, Cu, Mn and Ba) and sulfhydryl (S-H) groups on the ATTR amyloid fibril. Cardiac innervation imaging agents (e.g. effective in hereditary ATTR amyloidosis [26, 27] . Progression of peripheral polyneuropathy almost ceases entirely and progression of cardiac manifestations may also be halted, or even reversed [28] . Another treatment approach for ATTR CA is stabilization of the TTR tetramer, thereby interfering with the supply of precursor protein and resulting in slowing down of disease progression [29] . Molecular imaging should be able to visualize regression of CA under these new treatment regimens, but data are lacking at this moment. However, these new drugs probably do not inhibit synthesis of variant transthyretin by the choroid plexus in the central nervous system (CNS) leading to meningeal-vascular ATTRv amyloid deposition in the long-term, i.e. 10-15 years. This may become a new challenge in ATTRv patients, as these drugs are expected to improve life expectancy far beyond the current survival without treatment. Future studies with molecular imaging are necessary to assess the extent of the CNS manifestations.
11 C-Pib-PET scan currently appears to be the best imaging technique for early detection of these CNS manifestations, by showing-in a presymptomatic state-a pattern different from that seen in Alzheimer's disease [30] . Imaging with 18 F-florbetaben-PET/CT is also promising as it may visualize both intra-cerebral deposition of amyloid as well as deposition in other organs, particularly the heart.
Several treatments aiming at promoting amyloid removal are currently being investigated. These treatments, based on the use of monoclonal antibodies and small compounds, employ immunological mechanisms to clear amyloid deposits. Understanding the biochemical structure of amyloid fibrils and the composition of amyloid deposits has been and is of great importance in the development of these drugs. Proteomics may teach us about the specific composition of amyloid and surrounding tissue in order to develop new tracers that specifically target cardiac amyloid [31, 32] . Molecular imaging might be used in the development of new drugs to confirm the binding of compounds or antibodies to the amyloid in vivo (see Fig. 1 ). As already stated, molecular imaging is also going to play an important role by visualizing the effects of these treatments on the amyloid load.
In summary, a bright future lies ahead for molecular imaging in defining CA, the extent of systemic amyloid manifestations and in treatment monitoring. For diagnostic considerations, specific target imaging using hybrid or multimodality techniques such as PET/MR definitely will play a role in the future. Simultaneous combination of myocardial functional patterns, tissue characterization and visualizing specific targets in CA will yield a potential advantage of PET/MRI application. Several aspects have to be elucidated yet, but as therapeutic possibilities in amyloidosis finally break through, molecular imaging might be a perfect tool to guide the clinician in treating the patient. Ethical approval This article does not contain any studies with human participants performed by any of the authors.
